Ironwood Pharmaceuticals (IRWD) Research & Development (2010 - 2026)

Ironwood Pharmaceuticals has reported Research & Development for 17 years, with the latest figure at $21.9 million in Q1 2026.

• Quarterly Research & Development fell 20.02% year-over-year to $21.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.6 million (down 20.7% YoY) and the FY2025 annual result came in at $95.1 million, down 14.62% from the prior year.
• Research & Development was little changed at $21.9 million in Q1 2026 per IRWD's latest filing, from $21.9 million in the prior quarter.
• Over five years, Research & Development peaked at $35.7 million in Q4 2023 and troughed at $6.0 million in Q2 2023.
• A 5-year average of $21.2 million and a median of $22.5 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2024: Research & Development plunged 67.2% in 2022, then surged 406.47% in 2024.
• Over 5 years, Research & Development stood at $10.4 million in 2022, then soared by 241.53% to $35.7 million in 2023, then dropped by 28.83% to $25.4 million in 2024, then dropped by 13.89% to $21.9 million in 2025, then gained by 0.35% to $21.9 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $21.9 million, $21.9 million, and $22.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.